Roche Pharma Research and Early Development (pRED)

Our scientists are moving away from simply working toward developing treatments to taking a more holistic approach across diagnostics and pharmaceuticals, so that we may one day chart a new course in Alzheimer’s management, having an impact on the lives of so many throughout the patient journey.

Our goal is to optimise outcomes for patients and address the causes of vision loss in retinal disease to maintain long-term vision gains. At the same time, we want to lower the burden of treatment for patients and potentially make treatment less burdensome for their relatives and caregivers.

The Brainshuttleᵀᴹ technology has created enormous momentum in the industry. We’ve flipped the conversation from if it works to how well it works.

I am very proud to work for Roche because we have this commitment to antibiotics and global health security. You see our people's commitment level and the passion they bring. They raised their hands to be part of this important effort to help save lives around the world.

Changing intrathecal injection to peripheral administration [e.g. intravenous or subcutaneous injection] would mean reducing the treatment burden for patients and could revolutionise their care journey.